Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

171
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
171
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

209
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
209
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

4.0K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
4.0K
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

205
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
205
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

248
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
248
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

246
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
246

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.

Journal for immunotherapy of cancer·2026
Same author

Patient Perspectives regarding Artificial Intelligence-Driven Trichoscopy for Alopecia Evaluation.

Skin appendage disorders·2026
Same author

Racial and Ethnic Disparities in Persistent Chemotherapy-Induced Alopecia Among Women With Breast Cancer.

JAMA network open·2026
Same author

Antimicrobial Exposure and Immune-Related Cutaneous Adverse Events During Immune Checkpoint Blockade Therapy.

JAMA dermatology·2025
Same author

Adverse effects of scalp cooling for the reduction of chemotherapy-induced alopecia: A systematic review and meta-analysis.

Breast cancer research and treatment·2025

Related Experiment Video

Updated: Apr 12, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

1.4K

Management of dermatologic toxicities.

Mario E Lacouture1

  • 1Presented by Mario E. Lacouture, MD, Associate Professor of Dermatology at Cornell University and Associate Member of Memorial Sloan Kettering Cancer Center, New York, New York.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 22, 2015
PubMed
Summary

Cancer therapies, especially targeted treatments, frequently cause dermatologic toxicities. Oncologists need proactive strategies to manage side effects like rash and alopecia, ensuring optimal patient care and treatment adherence.

More Related Videos

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis
07:08

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis

Published on: August 31, 2022

2.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K

Related Experiment Videos

Last Updated: Apr 12, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

1.4K
Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis
07:08

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis

Published on: August 31, 2022

2.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K

Area of Science:

  • Oncology
  • Dermatology

Background:

  • Cancer therapies, particularly targeted treatments, are increasingly associated with dermatologic toxicities.
  • These side effects can significantly impact patient quality of life and treatment adherence.

Purpose of the Study:

  • To provide clinicians with essential strategies for managing common dermatologic toxicities in cancer patients.
  • To emphasize the importance of a proactive approach in preventing and treating these adverse events.

Main Methods:

  • Review of common dermatologic toxicities associated with cancer therapies.
  • Discussion of management strategies for rash, paronychia, and alopecia.
  • Recommendations for oncologists on integrating dermatologic care into cancer treatment plans.

Main Results:

  • Dermatologic toxicities are a growing concern with modern cancer treatments.
  • Effective management strategies exist for common side effects such as rash, paronychia, and alopecia.
  • Oncologist familiarity with managing these toxicities is crucial for patient care.

Conclusions:

  • A proactive and informed approach by oncologists is essential for managing cancer therapy-related dermatologic toxicities.
  • Effective management can improve patient comfort and allow for optimal dosing of anti-cancer drugs.
  • Clinicians should be prepared to address a range of skin-related side effects in patients undergoing cancer treatment.